Long-term hemodynamic and clinical efficacy of captopril therapy in ambulatory management of severe chronic congestive heart failure

Najam A. Awan, Ezra A Amsterdam, John Hermanovich, William J Bommer, Kathleen E. Needham, Dean T. Mason

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

The 6-month extended vasodilator efficacy of the oral angiotensin converting enzyme (ACE) inhibitor, captopril (CPT), was evaluated by sequential cardiac catheterization, nuclear scintigraphy, echocardiography, treadmill exercise, and symptomatology in nine patients with severe chronic left ventricular (LV) failure (CHF). CPT lowered LV filling pressure from 23 to 14 mm Hg acutely (p < 0.001) and to 14 mm Hg (p < 0.01) with continuous 6-month therapy; concomitantly CPT raised cardiac index from 2.03 to 2.46 L/min/m2 initially (p < 0.02) and to 2.33 L/min/m2 (p < 0.02) at 6 months. Simultaneously CPT raised LV ejection fraction from 0.21 to 0.25 acutely (p < 0.01) and to 0.30 (p < 0.01) at 6 months, and lowered LV end-diastolic dimension from 65 to 61 mm acutely (p < 0.001) and to 60 mm (p < 0.001) at 6 months. These beneficial actions of CPT on LV pump function raised treadmill exercise duration from 339 to 426 seconds initially (p < 0.05) and to 499 seconds (p < 0.05) at 6 months, while considerably reducing CHF symptomatology (p < 0.001). Thus ACE inhibition by CPT provides markedly beneficial sustained hemodynamic and clinical improvement in advanced LV failure without fluid accumulation or late vasodilator drug tolerance.

Original languageEnglish (US)
Pages (from-to)474-479
Number of pages6
JournalAmerican Heart Journal
Volume103
Issue number4 PART 1
DOIs
StatePublished - 1982

Fingerprint

Captopril
Heart Failure
Hemodynamics
Vasodilator Agents
Therapeutics
Exercise
Drug Tolerance
Peptidyl-Dipeptidase A
Ventricular Pressure
Cardiac Catheterization
Left Ventricular Function
Angiotensin-Converting Enzyme Inhibitors
Radionuclide Imaging
Stroke Volume
Echocardiography

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Long-term hemodynamic and clinical efficacy of captopril therapy in ambulatory management of severe chronic congestive heart failure. / Awan, Najam A.; Amsterdam, Ezra A; Hermanovich, John; Bommer, William J; Needham, Kathleen E.; Mason, Dean T.

In: American Heart Journal, Vol. 103, No. 4 PART 1, 1982, p. 474-479.

Research output: Contribution to journalArticle

@article{c5c70cd6236640fdb12db20ff8df99b5,
title = "Long-term hemodynamic and clinical efficacy of captopril therapy in ambulatory management of severe chronic congestive heart failure",
abstract = "The 6-month extended vasodilator efficacy of the oral angiotensin converting enzyme (ACE) inhibitor, captopril (CPT), was evaluated by sequential cardiac catheterization, nuclear scintigraphy, echocardiography, treadmill exercise, and symptomatology in nine patients with severe chronic left ventricular (LV) failure (CHF). CPT lowered LV filling pressure from 23 to 14 mm Hg acutely (p < 0.001) and to 14 mm Hg (p < 0.01) with continuous 6-month therapy; concomitantly CPT raised cardiac index from 2.03 to 2.46 L/min/m2 initially (p < 0.02) and to 2.33 L/min/m2 (p < 0.02) at 6 months. Simultaneously CPT raised LV ejection fraction from 0.21 to 0.25 acutely (p < 0.01) and to 0.30 (p < 0.01) at 6 months, and lowered LV end-diastolic dimension from 65 to 61 mm acutely (p < 0.001) and to 60 mm (p < 0.001) at 6 months. These beneficial actions of CPT on LV pump function raised treadmill exercise duration from 339 to 426 seconds initially (p < 0.05) and to 499 seconds (p < 0.05) at 6 months, while considerably reducing CHF symptomatology (p < 0.001). Thus ACE inhibition by CPT provides markedly beneficial sustained hemodynamic and clinical improvement in advanced LV failure without fluid accumulation or late vasodilator drug tolerance.",
author = "Awan, {Najam A.} and Amsterdam, {Ezra A} and John Hermanovich and Bommer, {William J} and Needham, {Kathleen E.} and Mason, {Dean T.}",
year = "1982",
doi = "10.1016/0002-8703(82)90332-5",
language = "English (US)",
volume = "103",
pages = "474--479",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "4 PART 1",

}

TY - JOUR

T1 - Long-term hemodynamic and clinical efficacy of captopril therapy in ambulatory management of severe chronic congestive heart failure

AU - Awan, Najam A.

AU - Amsterdam, Ezra A

AU - Hermanovich, John

AU - Bommer, William J

AU - Needham, Kathleen E.

AU - Mason, Dean T.

PY - 1982

Y1 - 1982

N2 - The 6-month extended vasodilator efficacy of the oral angiotensin converting enzyme (ACE) inhibitor, captopril (CPT), was evaluated by sequential cardiac catheterization, nuclear scintigraphy, echocardiography, treadmill exercise, and symptomatology in nine patients with severe chronic left ventricular (LV) failure (CHF). CPT lowered LV filling pressure from 23 to 14 mm Hg acutely (p < 0.001) and to 14 mm Hg (p < 0.01) with continuous 6-month therapy; concomitantly CPT raised cardiac index from 2.03 to 2.46 L/min/m2 initially (p < 0.02) and to 2.33 L/min/m2 (p < 0.02) at 6 months. Simultaneously CPT raised LV ejection fraction from 0.21 to 0.25 acutely (p < 0.01) and to 0.30 (p < 0.01) at 6 months, and lowered LV end-diastolic dimension from 65 to 61 mm acutely (p < 0.001) and to 60 mm (p < 0.001) at 6 months. These beneficial actions of CPT on LV pump function raised treadmill exercise duration from 339 to 426 seconds initially (p < 0.05) and to 499 seconds (p < 0.05) at 6 months, while considerably reducing CHF symptomatology (p < 0.001). Thus ACE inhibition by CPT provides markedly beneficial sustained hemodynamic and clinical improvement in advanced LV failure without fluid accumulation or late vasodilator drug tolerance.

AB - The 6-month extended vasodilator efficacy of the oral angiotensin converting enzyme (ACE) inhibitor, captopril (CPT), was evaluated by sequential cardiac catheterization, nuclear scintigraphy, echocardiography, treadmill exercise, and symptomatology in nine patients with severe chronic left ventricular (LV) failure (CHF). CPT lowered LV filling pressure from 23 to 14 mm Hg acutely (p < 0.001) and to 14 mm Hg (p < 0.01) with continuous 6-month therapy; concomitantly CPT raised cardiac index from 2.03 to 2.46 L/min/m2 initially (p < 0.02) and to 2.33 L/min/m2 (p < 0.02) at 6 months. Simultaneously CPT raised LV ejection fraction from 0.21 to 0.25 acutely (p < 0.01) and to 0.30 (p < 0.01) at 6 months, and lowered LV end-diastolic dimension from 65 to 61 mm acutely (p < 0.001) and to 60 mm (p < 0.001) at 6 months. These beneficial actions of CPT on LV pump function raised treadmill exercise duration from 339 to 426 seconds initially (p < 0.05) and to 499 seconds (p < 0.05) at 6 months, while considerably reducing CHF symptomatology (p < 0.001). Thus ACE inhibition by CPT provides markedly beneficial sustained hemodynamic and clinical improvement in advanced LV failure without fluid accumulation or late vasodilator drug tolerance.

UR - http://www.scopus.com/inward/record.url?scp=0020352941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020352941&partnerID=8YFLogxK

U2 - 10.1016/0002-8703(82)90332-5

DO - 10.1016/0002-8703(82)90332-5

M3 - Article

VL - 103

SP - 474

EP - 479

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 4 PART 1

ER -